Nature Communications · 2019 · 63 citations · 54 references
Veterinary MedicineInfectious DiseasesPharmacologyDrug DesignDrug DiscoveryHost-pathogen InteractionsAntifungal PharmacologyParasitic Disease PathogenesisParasitic PathogenesisProtozoal InfectionsProtozoan Host-parasite InteractionsProtozoan PathogenesisAntiprotozoal Drug DevelopmentAntiprotozoal Drug TherapyAntiprotozoal PharmacologyCryptosporidial AgentsCryptosporidiosis TreatmentMurine ModelsNeglected Tropical Disease MedicinesParasite Development
Cryptosporidiosis is a leading cause of life-threatening diarrhea in young children and causes chronic diarrhea in AIDS patients, but the only approved treatment is ineffective in malnourished children and immunocompromised people. We here use a drug repositioning strategy and identify a promising anticryptosporidial drug candidate. Screening a library of benzoxaboroles comprised of analogs to four antiprotozoal chemical scaffolds under pre-clinical development for neglected tropical diseases for Cryptosporidium growth inhibitors identifies the 6-carboxamide benzoxaborole AN7973. AN7973 blocks intracellular parasite development, appears to be parasiticidal, and potently inhibits the two Cryptosporidium species most relevant to human health, C. parvum and C. hominis. It is efficacious in murine models of both acute and established infection, and in a neonatal dairy calf model of cryptosporidiosis. AN7973 also possesses favorable safety, stability, and PK parameters, and therefore, is an exciting drug candidate for treating cryptosporidiosis.
54
Karen L. Kotloff, James P. Nataro, William C. Blackwelder et al. · The Lancet · 2013 · 3.6K citations
Leonard D. Shultz, Bonnie Lyons, Lisa Burzenski et al. · The Journal of Immunology · 2005 · 1.7K citations · Full text